Par Pharmaceuticals agrees $100m patent settlement
Par Pharmaceuticals has agreed to pay $100 million to a unit of Salix Pharmaceuticals and the University of Missouri to settle a lawsuit alleging it had infringed two patents related to the heartburn drug Zegerid
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: